Table 6 Clinicopathological variables associated with optimal cytoreduction in patients with uterine sarcoma

Age at recurrence (years)

 < 60

17 (56.7)

1

 ≥ 60

3 (42.9)

1.744

0.331–9.189

0.512

ECOG performance status before SCS

 0

17 (53.1)

1

 1–2

3 (60.0)

0.756

0.111–5.149

0.775

FIGO stage at initial diagnosis

 I/II

16 (50.0)

1

 III/IV

4 (80.0)

0.250

0.025–2.489

0.237

Histology

 Uterine leiomyosarcoma

9 (47.4)

1

 Low-grade endometrial stromal sarcoma

6 (57.5)

0.750

0.169–3.327

0.705

 High-grade endometrial stromal sarcoma

2 (66.7)

0.450

0.035–5.843

0.542

 Other

3 (75.0)

0.300

0.026–3.427

0.333

Clinical symptoms at recurrence

 No

10 (52.6)

1

 Symptomatic

10 (55.6)

0.889

0.244–3.243

0.858

Size of largest tumor (cm)

 ≤ 6

11 (57.9)

1

 > 6

9 (50.0)

1.375

0.376–5.032

0.630

Number of recurrent tumors

 One

12 (92.3)

1

1

 Several

8 (33.3)

24.000

2.634-218.666

0.005

19.589

1.902-201.718

0.012

DFI before SCS (months)

 < 12

9 (40.9)

1

 ≥ 12

11 (73.3)

0.252

0.061–1.047

0.058

Retroperitoneal lymph node metastasis

 No

19 (54.3)

1

 Yes

1 (50.0)

1.187

0.069–20.539

0.906

Distant metastasis

 No

18 (54.5)

1

 Yes

2 (50.0)

1.200

0.150–9.570

0.863

Peritoneal dissemination

 No

15 (68.2)

1

1

 Yes

5 (33.3)

4.286

1.058–17.363

0.041

1.533

0.291–8.061

0.614

Extended beyond the pelvis

 No

9 (47.4)

1

 Yes

11 (61.1)

0.573

0.155–2.117

0.403

Ascites

 None

18 (52.9)

1

 Yes

2 (66.7)

0.563

0.046–6.806

0.651